Results 111 to 120 of about 13,683 (246)

Study protocol: Comparison of the effect of treatment with Nonsteroidal anti- inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti- tumour necrosis factor a therapy alone on progression of Structural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) – an open-label randomized controlled multicenter trial [PDF]

, 2017
Introduction There is some evidence that non-steroidal anti-inflammatory drugs (NSAIDs), in particular celecoxib, might possess not only a symptomatic efficacy but also disease-modifying properties in ankylosing spondylitis (AS), retarding the ...
Listing, Joachim, Muche, Burkhard, Poddubnyy, Denis, Proft, Fabian, Rios-Rodriguez, Valeria, Sieper, Joachim   +5 more
core   +1 more source

Integration of Metabolomics and 16S Ribosomal RNA Sequencing to Elucidate the Pathogenesis of Ankylosing Spondylitis

Immunity, Inflammation and Disease, Volume 13, Issue 3, March 2025.
Disrupted gut microbiota and altered metabolites are present in AS patients. The analysis of microbiome and metabolomic data revealed significant differences between AS patients and HCs. ABSTRACT Objective Despite growing interest in the gut microbiota and blood metabolome in patients with ankylosing spondylitis (AS), its role remains poorly understood.
Xin Wang, Haojie Xu, Yuyan Chao, Chao Sun, Tingting Wang, Xiaoyun Fan, Lin Tang, Shengqian Xu, Changhao Xie   +8 more
wiley   +1 more source

Avaliação da aterosclerose subclínica e de níveis plasmáticos de LDL minimamente modificada em pacientes com espondilite anquilosante e sua correlação com a atividade da doença [PDF]

, 1931
IntroductionAccelerated atherosclerosis has been shown in some autoimmune diseases, mainly in Systemic Lupus Erythematosus and Rheumatoid Arthritis. Although high preva- lence of corticosteroids use may be a confounding factor due to their detrimental ...
Fernanda Teles Ceccon, Valderílio Feijó Azevedo, Carlos A. Engelhorn, Dulcinéia S.P. Abdalla, Tanize E.S. Faulin, Luis Cesar Guarita-Souza, Roberto Pecoits-Filho, José Rocha Faria-Neto, Berliner, Ross, Virella, Tsimikas, Witztum, Cazzolato, Paramo, Manzi, Dhawan, Troelsen, Sattar, Turesson, Kim, Azevedo, Divecha, Van Der Linden, Demuth, Avogaro, Lorenz, Milovanovic, Avouac, Sari, Mano, Manzi, Del Rincon, Mathieu, Frostegard, Cushing, Shih, Damasceno, Hahn, Peters, Bruce, Davis   +41 more
core   +2 more sources

Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo‐Controlled, Phase 3 Study

Arthritis &Rheumatology, Volume 77, Issue 2, Page 163-170, February 2025.
Objective Our goal was to assess the efficacy and safety of intravenous (IV) secukinumab for the treatment of adults with active axial spondyloarthritis (axSpA) in INVIGORATE‐1. Methods INVIGORATE‐1 (NCT04156620) was a randomized, double‐blind, parallel‐group, phase 3 trial in patients with active axSpA (either radiographic or nonradiographic ...
Atul Deodhar, Jerzy Supronik, Alan Kivitz, Guillermo Valenzuela, Karen Kapur, Susanne Rohrer, Eva Dokoupilová, Hanno B. Richards, Karel Pavelka   +8 more
wiley   +1 more source

B Cell Receptor Repertoire Analysis of the CD21lo B Cell Compartment in Healthy Individuals, Patients With Sjögren's Disease, and Patients With Radiographic Axial Spondyloarthritis

European Journal of Immunology, Volume 55, Issue 2, February 2025.
This study demonstrates that CD27−CD21lo B cells harbor a relatively low frequency of somatic mutations in their BCR compared with CD27+CD21lo B cells and early plasmablasts. Clonal relationships were present among all three subsets in both health and disease, indicating that CD27−CD21lo B cells actively contribute to immune responses. ABSTRACT B cells
Rick Wilbrink, Linda van der Weele, Anneke J. P. L. Spoorenberg, Niek de Vries, Ilse T. G. Niewold, Gwenny M. Verstappen, Frans G. M. Kroese   +6 more
wiley   +1 more source

Psychometric Properties of the Persian Version of the Evaluation of Ankylosing Spondylitis Quality of Life (EASi‐QoL) and Ankylosing Spondylitis Disease Activity Score (ASDAS) Questionnaires: A Cross‐Sectional Study

Health Science Reports, Volume 8, Issue 2, February 2025.
ABSTRACT Background and Aims Ankylosing spondylitis (AS) is a chronic inflammatory disease that affects quality of life (QoL) due to its impact on physical and emotional well‐being. Accurate and reliable tools are needed to assess disease activity and QoL in different cultural contexts.
Maryam Hosseini, Amirmasoud Kazemzadeh Houjaghan, Ghazal Behzad, Sahar Ghorbanpour, Seyede Zahra Emami Razavi, Mohaddeseh Azadvari, Shafieh Movaseghi, Negar Salaminour   +7 more
wiley   +1 more source

Microbiota and chronic inflammatory arthritis. an interwoven link [PDF]

, 2016
Background: Only recently, the scientific community gained insights on the importance of the intestinal resident flora for the host's health and disease.
D'Amelio, Raffaele, Laganà, Bruno, Manuela Rosado, M, Picchianti Diamanti, Andrea   +3 more
core   +2 more sources

Facilitators and Barriers to Physical Activity for Patients With Rheumatoid Arthritis and Axial Spondyloarthritis

International Journal of Rheumatic Diseases, Volume 28, Issue 2, February 2025.
ABSTRACT Background Physical activity is important in patients with rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA). Current literature suggests they engage in less physical activity compared to healthy controls. Reasons for this discrepancy has not been well studied in Asian populations.
Annabel Zhi Yan Lee, Ting Hui Woon, Charmaine Tze May Wang, Yu Heng Kwan, Warren Fong   +4 more
wiley   +1 more source

Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study [PDF]

, 2017
AIM To report adalimumab (Ada) efficacy on articulargastrointestinal disease and health-related quality of life (HRQoL) in patients with enteropathic spondyloarthritis (ES).
Benfaremo, D., Bolognini, L., Ciccia, F., Ciferri, M., Farinelli, A., Gabrielli, A., Luchetti, M., Mosca, P., Rossini, M., Triolo, G.   +9 more
core   +1 more source

Safety and effectiveness of secukinumab subcutaneous injection in Japanese patients with psoriasis vulgaris and psoriatic arthritis: A post‐marketing surveillance

The Journal of Dermatology, Volume 52, Issue 1, Page 11-23, January 2025.
Abstract Secukinumab is the first human monoclonal antibody that targets human interleukin‐17A. This open‐label, multicenter, uncontrolled, single‐arm, prospective observational surveillance evaluated the long‐term safety and effectiveness of secukinumab in patients with psoriasis vulgaris and psoriatic arthritis (PsA) in Japan.
Ayako Fujishige, Noriko Seko
wiley   +1 more source